College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Cevac Meta L lyophilisate for suspension for chickens

NL/V/0200/001

December 2016

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0200/001/DC
Name, strength and pharmaceutical form	Cevac Meta L lyophilisate for suspension for chickens
Applicant	Ceva-Phylaxia Veterinary Biologicals Co. Ltd., 1107, Budapest, Szállás u. 5., Hungary.
Active substance(s)	Live attenuated avian metapneumovirus
ATC Vetcode	QI01AD01
Target species	Chicken
Indication for use	For active immunisation of future layer chickens in order to reduce respiratory signs and virus shedding associated with infection by avian metapneumovirus which is known to be the primary etiological agent of Swollen Head Syndrome.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Full application in accordance with Article 12 (3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	29 June 2016
Date product first authorised in the Reference Member State (MRP only)	
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IT, LT, LV, PL, PT, RO, SE, SK, UK.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains live attenuated avian metapneumovirus subtype B, strain CRR126 min. 2.5 log10 $TCID_{50}$ and max. 3.8 log10 $TCID_{50}$, and excipients sucrose, lactose, sorbitol, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, gelatin and water for injections.

The container consists of a clear glass vial of hydrolytic glass type I, closed with bromobutyl stoppers and sealed with aluminium caps. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of vaccine strain is justified.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is live avian metapneumovirus, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

Starting materials of non-biological origin used in production comply with the European Pharmacopoeia (Ph. Eur.) monographs where these exist. For the substances where there is no such requirement the company has identified the source of the substance, explained how its quality is controlled and provided relevant certificates of analysis.

Biological starting materials used are in compliance with the relevant Ph. Eur. Monographs and guidelines and are appropriately screened for the absence of extraneous agents according to the Ph. Eur.; any deviation was adequately justified.

The master and working seeds have been produced according to the Seed Lot System as described in the relevant guideline.

D. Control tests during production

The tests performed during production are described and the results of 4 consecutive runs, conforming to the specifications, are provided.

E. Control Tests on the Finished Product

The tests performed on the final product conform to the relevant requirements; any deviation from these requirements is justified. The tests include in particular appearance, residual moisture, identity, potency, sterility, mycoplasmas and extraneous agents.

The demonstration of the batch to batch consistency is based on the results of 4 batches produced according to the method described in the dossier. Other supportive data provided confirm the consistency of the production process.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 2-hour in-use stability is based on the demonstration of stability for two batches reconstituted in water and stored for 2 hours at room temperature.

G. Other Information

None.

III. SAFETY ASSESSMENT

Laboratory trials

The safety of the administration of one dose, an overdose and the repeated administration of one dose in the target animal were demonstrated in Day-old SPF chickens. The investigation was performed according to the recommendations of Directive 2001/82/EC as amended and the relevant guidelines. No adverse reactions attributable to the vaccine were seen.

Effects on the reproductive tract were examined, the product is safe for use in birds prior to lay. No studies have been performed in birds during lay, a relevant warning is included in the SPC.

Spread of the vaccine strain was examined, the vaccine strain spreads to unvaccinated birds. Spread to non-target species was examined using turkeys, the vaccine strain may spread to turkeys and cause mild respiratory signs in that species. Appropriate warnings regarding spread as well as measures to limit spread of the vaccine strain are included in the SPC.

No specific assessment of the interaction of this product with other medicinal product was made. Therefore, an appropriate warning in the SPC is included.

Field studies

As this product is considered to fall under the Guideline for Minor Use and Minor Species (MUMS), safety field trails may be omitted if safety is sufficiently proven in laboratory studies. Since the vaccine showed no adverse reactions in the laboratory studies, the omission of safety field data is considered justified.

Environmental Risk Assessment

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment was required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

IV. CLINICAL ASSESSMENT (EFFICACY)

Laboratory Trials

The efficacy of the product has been demonstrated in laboratory studies in accordance with the relevant requirements.

Two vaccine batches, at a passage level of MSV+5 were used in efficacy studies. These vaccine batches were diluted to contain the minimum titre per dose.

The efficacy was evaluated in challenge experiments.
In one study, a suitable number of day-old SPF chicks were vaccinated by eyedrop. An unvaccinated control group was included in the study. All animals were challenged with aMPV virus 3 weeks after vaccination. The animals were monitored for clinical signs and virus shedding. After challenge infection, the efficacy of the vaccine was demonstrated by reduction of clinical signs and reduction of shedding of aMPV virus.

Similarly designed studies were performed in day-old commercial chicks and 5week old commercial layers after application via eye-drop and coarse spray respectively. After challenge infection, the efficacy of the vaccine was shown in MDA positive animals by reduction of clinical signs and reduction of shedding of aMPV virus.

The duration of immunity was determined in day-old commercial chicks and 5week old commercial layers after eye-drop or spray application respectively. Challenge was performed at 9-weeks after vaccination. The efficacy of the vaccine was demonstrated by reduction of clinical signs and reduction of shedding of aMPV virus.

No specific assessment of the interaction of this product with other medicinal product was made. Therefore, an appropriate warning in the SPC is included.

Field Trials

As this product is considered to fall under the Guideline for Minor Use and Minor Species (MUMS), efficacy field trails may be omitted if efficacy is sufficiently proven in laboratory studies. Since efficacy was sufficiently supported by data from laboratory studies performed in commercial chickens, the omission of efficay field data is considered justified.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Vetrinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None.